FindTrial
Sign In

Per-procedural ablation zone imaging with MRI during radiofrequency ablation of locally irresectable pancreatic cancer

Per-procedural ablation zone imaging with MRI during radiofrequency ablation of locally irresectable pancreatic cancer - PRECISE: Ablation zone imaging with MRI during RFA of irresectable LAPC

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON45396
Enrollment
20
Registered
2017-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer Pancreatic tumor

Interventions

pancreatic cancer

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Participation in PELICAN-trial and randomized for RFA-treatment

Exclusion criteria

Exclusion criteria: Contra-indications to undergo MR imaging Impossibility to obtain informed consent

Design outcomes

Primary

MeasureTime frame
Primary outcome is to assess the feasibility of real-time MRI temperature monitoring during RFA of locally irresectable pancreatic cancer.—

Secondary

MeasureTime frame
Secondary outcomes are assessment of correlation of per-procedural MRI-guided delineated zone of ablation with ablation effect on CT scan day 7 after RFA and verification on intraoperative MRI of the localization, distance to adjacent structures and position within the tumour of the ultrasound guidance placed needles.—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)